Say Hello to Better Diabetes Management with iGlucose

This article was originally posted on SmallCapVoice.com.

Say Hello to Better Diabetes Management
On April 13, PositiveID Corporation (OTCBB: PSID) began taking pre-orders for its FDA-cleared iglucose(R) mobile health system for diabetes management from interested consumers providers. iglucose is a unique device that simplifies the process of diabetes management making it easier for patients to accurately and effectively self-manage their glucose levels for better health. With approximately 26 million diabetic people in US, the potential impact of this device is astounding.

What Is iglucose?
iglucose is a unique device that communicates data wirelessly from glucometers to the iglucose diabetes management portal, allowing diabetes patients to share data in real time with family members and health care professionals. By eliminating the need for log keeping, iglucose puts diabetes management back in the hands of the patients.

 

iglucose Available to Rural Healthcare Providers
Since most diabetes patients need to be checked by a health care professional every 90 days, the realistic option for accurate self-management will make regular treatment a possibility for those patients who live outside major cities, in small towns and rural areas. Because iglucose transmits data electronically and wirelessly, a patient’s glucose levels can be shared at any time with health care professionals, even thousands of miles apart. The rural healthcare market includes a range of areas including rural practitioners, administrators and clinic directors. Social worker, state and federal employees based and even academics can benefit from the iglucose system.

iglucose is Designed for Convenience
Truly a smart device, iglucose can create different reports based on the user’s preferences. The range of options includes e-mail, fax or even SMS text. Plus, iglucose doesn’t even need a cell phone or wireless plan to transmit data. It simply works like magic, delivering accurate data in practically no time at all. iglucose truly makes self-management for individuals diagnosed with diabetes hassle-free. Online enrollment takes only a few minutes and once enrolled, setup is easy. Simply connect the iglucose device to a compatible, data capable glucometer and levels are automatically sent to the secure iglucose database. The iglucose system was designed to be compatible with a wide range of FDA-cleared blood glucose meters including Johnson & Johnson LifeScan(R), Abbott FreeStyle(R), Nipro Diagnostic(TM) True(TM) and Bayer Contour(R) monitoring systems. iglucose will collect and transmit data from any of these devices to a secure database using wireless technology.

Demand Builds for iGlucose
“The response to iglucose from our customers and prospects is overwhelming,” claims Scott Griffin, Chief Operating Officer of Merge-MD, a company that believes electronic health records should follow the patient in real-time. By making important data so easily accessible, healthcare providers can make faster, safer choices for patients. Having access to this type of data facilitates more meaningful conversation between patients and healthcare professionals. Not only does this reduce expense by eliminating unnecessary care, but it also improves the overall quality of the care received.

Pre-order iglucose Online
Want to be the first to get your hands on this revolutionary medical device? PositiveID Corporation is currently accepting pre-orders for iglucose on their website. “As we complete the final stages of preparing for the commercial launch of iglucose, we are pleased, based on consumer demand, to be able to provide the opportunity to pre-order this FDA-cleared system for diabetes management,” said PositiveID Chairman and CEO, William J. Caragol. The company plans to launch iglucose commercially soon, in the second quarter of 2012.

iglucose Encourages Patient Management
Since iglucose can create various types of reports and seamlessly communicates accurate data wirelessly, it effectively eliminates the need for keeping a logbook of a patient’s health. iglucose truly encourages better self-management among diabetes patients. This device uses mobile technology to transmit blood glucose levels from glucometers to be shared with anyone in automatically. Through the online diabetes management portal, users can view custom reports and logbooks automatically generated by the web application. Users can easily maintain control over who has access to their health data and exactly how that information gets presented and communicated.

See iglucose in Action for Yourself
Sometimes technology reminiscent of futuristic sci-fi movies simply must be seen to be fully realized. iglucose will be demonstrated at the national rural health Association 35th annual rural health conference in Denver, Colorado. Stop by booth #213 on April 17-20, 2012 at the Hyatt Regency Denver, Colorado Convention Center, and see this futurist technology for yourself, alongside innovative healthcare solutions provider Merge-MD, a company devoted to coordinating information technology processes and people to advance the quality of healthcare. Through the conference, PositiveID hopes to introduce iglucose to a wide range of individuals with an interest in rural health care, such as rural health practitioners, clinic directors, and even lay health workers like social workers, state and federal health employees, and health workers in the academic fields.

An innovative emerging growth company and developer of advanced technologies, PositiveID has developed several revolutionizing products for diabetes management and rapid medical testing, as well as advanced airborne bio-threat detection systems for United States homeland defense.

About SmallCapVoice.com

SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the penny stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in small cap stocks and micro cap stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.

IMPORTANT DISCLAIMER – PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications.

Contact:Stuart T. Smith CEO
512-267-2430
ssmith@smallcapvoice.com
http://www.smallcapvoice.com

Medical Marijuana Inc.: Pioneers of a Budding Cannabis Industry Grow Bigger and Bigger

This article was originally posted on SmallCapVoice.com.

Hemp and Medical Marijuana Are Big Business

In the United States alone, marijuana is estimated to be a $110 billion market, with the medical market making up nearly $17 billion. Medical Marijuana Inc. (MJNA), the first publicly held company to emerge from the medical marijuana and industrial hemp market, has experienced an incredible 4000% increase in revenue, with even more growth expected in the future.

Amazingly, there are more than 55,000 uses for medical marijuana and industrial hemp. Since all of these industries are underdeveloped, undercapitalized and not being utilized fully, the potential for growth and expansion has yet to be realized.

 

Medical Marijuana Inc. Role in the Industry

In an industry comprised mostly of mom and pop businesses, Medical Marijuana Inc. aims at being the world’s premier innovator in the cannabis and hemp industries. The company is driven with passion to create awareness and maintains a heavy focus on sustainability. By maintaining a diverse portfolio, Medical Marijuana Inc. dominates a large share of the market. Each entity under the Medical Marijuana Inc. umbrella remains focused with a clearly defined purpose in relation to the development of other Medical Marijuana Inc. holdings, which include CannaBANK, The Hemp Network, The Pet Hemporium, MMI Nutraceuticals, MMI Biotechnology, and CannaFUEL.

The Amazing Healing Properties of Medical Marijuana

This miraculous herb can alleviate the symptoms of practically everything from hiccups to Multiple Sclerosis to depressive mental conditions. Not only can medical marijuana stop the spread of breast cancer, which kills more than 41,000 women each year. It also reduces inflammation and greatly reduces the growth rate of tumors in the lungs, breasts and brain, according to the American Association for Cancer Research.

Hemp Has Been Used Throughout the Ages

Since the beginning of recorded history, marijuana and the hemp plant have been used for a wide range of things from food to medicine to building materials, and even fuel. However, medicine in the Western world has forgotten what we once knew. Cannabis has been a mainstay in most of the world for hundreds of years.

The Amazing Healing Properties of Medical Marijuana

This miraculous herb can alleviate the symptoms of practically everything from hiccups to Multiple Sclerosis to depressive mental conditions. Not only can medical marijuana stop the spread of breast cancer, which kills more than 41,000 women each year. It also reduces inflammation and greatly reduces the growth rate of tumors in the lungs, breasts and brain, according to the American Association for Cancer Research.

Medical Marijuana Is Supported by Scientific Research

In the past, marijuana has been criticized heavily in the media for its recreational use. However, despite its quickly fading negative reputation, the movement towards medical marijuana as a healing tool has gained speed with support from scientific research that proves the positive health impact of this amazing age-old plant. California doctors report successful treatment with medical marijuana of more than 300,000 migraine cases. It also treats glaucoma, prevents seizures, help with ADD and ADHD and can prevent Alzheimer’s disease.

Limitations on the Medical Marijuana Industry

Although the medical marijuana industry’s obvious potential for enormous growth, the industry remains fractured by international, state and local laws. However, Medical Marijuana Inc. sees an opportunity in this. As the first publicly held company vested in a medical marijuana and industrial hemp industries, Medical Marijuana Inc. maintains a diverse portfolio of hemp and cannabis-based businesses ranging from hydroponics stores to pharmaceutical compounds made from parts of the hemp plant. The company has thrived through substantial change as this newly developing industry navigates its way through the violent political landscape of federal and state laws.

Building Awareness with the Hemp Network

Although the potential uses for marijuana and hemp are numerous, awareness of these amazing plant and its many uses remains low. Raising awareness and educating the general population about the benefits and healing properties of marijuana, and the practically infinite uses for hemp continues to be the Hemp Network’s primary objective. As the first network marketing company in history that provides consumers with hemp products on a network marketing platform, the Hemp Network creates opportunity for massive distribution of hemp and wellness related products to a wide marketplace and will be a driving force behind a growing movement towards hemp as a solution in America.

Hemp Products for Pets

Another more unique division of Medical Marijuana Inc. Encompasses the Pet Hemporium, a company that has developed a variety of everyday pet products that are made from hemp. From soft, hemp-based pet beds to leashes made with hemp to hemp chew toys, hemp tug ropes, and even hemp Frisbees, pet owners can feel safe knowing their dog’s toys are both naturally anti-bacterial and naturally anti-microbial. Although not available directly to consumers, The Pet Hemporium will soon offer wholesale pricing for distributors, as well as direct sales to national pet stores.

Hemp as a Fuel Source

CannaFUEL is a division of Medical Marijuana Inc. that oversees and coordinates research and development of hemp and other biomass-based fuels. Current CannaFUEL projects located in the United States, Canada and Guatemala are focused on syndicating biomass processing facilities and raw biomass materials for processing into usable biofuels.

Marijuana and Hemp Make for a Sustainable Planet

By creating a sustainable economy, CannaBANK will in turn will create a sustainable planet. CannaBANK acts as the Merger and Acquisitions arm of Medical Marijuana Inc. and stands committed to advancing the health and wellness industries while improving our world with environmentally-friendly sustainable processes for creating materials from renewable resources. As pioneers of the industry, CannaBANK’s work will benefit economies big and small, and the individuals affected by them.

Although Medical Marijuana Inc. does not grow or sell marijuana, the company is actively acquiring business and technology intersect and has secured $4 million in liquidity, non­recourse, non-dilution development financing this year alone.

About SmallCapVoice.com

SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the penny stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in small cap stocks and micro cap stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.

IMPORTANT DISCLAIMER – PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications.

Contact:Stuart T. Smith CEO
512-267-2430
ssmith@smallcapvoice.com
http://www.smallcapvoice.com

 

What is Bioagent Detection and How Is It Changing Our World?

This article was originally posted on smallcapvoice.com.

Since the tragic attacks of September 11th, 2001, and the terrifying Amerithrax case, the world has become ever so aware of the threat of biological warfare and how very real this threat is. However, innovative companies like PositiveID Corporation (OTCBB: PSID) and their subsidiary MicroFluidic Systems have developed a bioagent detection device that will change how our government and military fight biowarfare.

So, what is bioagent detection anyway? Bioagent detection devices test the air for the presence of deliberately-released biological pathogens that are dangerous enough to be used as a biological weapon. Bacillus anthracis, perhaps the most commonly-known bioagent, causes Anthrax, a typically fatal disease. Because some of these hazardous agents can be made from readily-found ingredients, the need for solid protection against these types of deadly attacks continues to grow.

During the weeks immediately following the September 11 attacks, letters containing highlydeadly anthrax spores were sent via the postal system to several prominent news anchors and media offices, as well as two U.S. Senators. Five people were killed and 17 others were infected. For weeks, American citizens were terrorized by news reports of potentially-lethal exposure and warned of the deathly affects. Fearing for their safety, American demanded protection.

In response, the government formed BioWatch, a program to detect the release of airborne pathogens intended as an attack on major United States cities. The program was described as “the nation’s first early warning network of sensors to detect biological attack” and has included a system of filters located within the Environmental Protection Agency’s air filters. Collected data is analyzed by the Centers for Disease Control and Prevention and suspected threats are passed on to the Federal Bureau of Investigation.

However, criticism of the BioWatch program has brought some potential issues to the forefront. Many have expressed concerns about relying on the BioWatch system alone and some have pointed out specific points of possible failure in the system, from poor placement of filters in locations that are not optimal or are likely to incur bio attacks, to sizable gaps in coverage. Some noted that the BioWatch filters kill whatever pathogen has activated them, subsequently eliminating the possibility of further scientific testing. Others claim the current filters would be unable to detect indoor or underground bioagent releases, and would therefore, fail to protect our country in an attack.

Since the birth of BioWatch, the U.S. government and Department of Homeland Security have remain focused on keeping us safe from bio warfare attacks and bioterrorism. Millions have been spent on research supporting the development of better detection devices. America’s demand for a better answer is stronger than ever.

Luckily, PositiveID Corporation’s (“PositiveID”) subsidiary MicroFluidic Systems (“MFS”) developed a bio-threat detection device called M-BAND that will drastically change the world’s ability to defend against bioterrorism.

Developed over eight years, under contract for the Department of Homeland Security (DHS), MBAND is an early warning system designed to detect the presence of intentionally-released aerosolized biological agents. For up to 30 days, M-BAND uses a biocell monitor, running autonomously, continuously collecting samples and analyzing the air. Designed to detect bacteria, viruses, and toxins, these machines can provide results within a mere three hours. Typically placed in high-traffic areas and networked together, M-BAND devices effectively monitor for air-borne pathogens by testing the air every 30 minutes and delivering results through a secure wireless network to a central location for extensive analysis.

After eight years of development, M-BAND offers a real solution. By providing real-time data, M-BAND provides awareness and protection against potential biological warfare attack. Furthermore, M-BAND can be remotely configured to test for all three pathogen types, both simultaneously at programmable intervals or any one in particular, including DNA-based pathogens, with or without either RNA-based organisms or toxins.

Among the bioagents that M-BAND can identify are strains of Bacillus anthracis, also known as anthrax, Yersinia pestis, responsible for causing Black Death and bubonic plague, Francisella tularensis, which causes tularemia or rabbit fever, Burkholderia mallei, which causes Glanders, and Burkholderia pseudomallei, the cause of melioidosis. Because these agents can kill so many people so quickly, an effective warning system is necessary and more important than ever to implement effective quarantine procedures as a line of defense.

The Department of Homeland Security has allocated $3 billion in the budget for bioaresol monitors to setup a network of early warning systems across the country. Luckily, among the large companies and organizations involved with bioagent detection, the unlikely underdog could save the day. The small-but-mighty PositiveID Corporation with M-BAND, an amazing biocell device, is changing the world of bioagent detection.

In a recent press release, PositiveID announced their upcoming presentation of their bioagent detection device called M-BAND at the 10th Annual American Society for Microbiology Biodefense and Emerging Diseases Research Meeting, scheduled to take place from February 26-29, 2012, in Washington, DC. Although smaller than some defense companies, PositiveID Corporation is making big waves on the BioWatch scene. By exhibiting with The Boeing Company, PositiveID stands to change the way the world fights bio warfare and bioterrorism.

SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the penny stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in small cap and micro cap stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.

IMPORTANT DISCLAIMER – PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications.

Contact:Stuart T. Smith CEO
512-267-2430
ssmith@smallcapvoice.com
http://www.smallcapvoice.com

3 New Devices That Are Revolutionizing Diabetes Management

This article was originally posted on smallcapvoice.com.

With an estimated 285 million people worldwide suffering from diabetes, the disease has become an epidemic and the problem continues to grow at a startling rate. As the second leading cause of death in the United States, more than 26 million U.S. residents have been diagnosed with diabetes. Advances in effective management are more necessary than ever before. Luckily, an innovative company called PositiveID Corporation (OTCBB: PSID) is developing three new products that could drastically improve the world of diabetes management.

EasyCheck™, a hand-held device, checks glucose levels in exhaled breath, thus making the traditional finger-pricking method unnecessary. A second product, cleverly called iglucose™, communicates wirelessly with a diabetic’s glucometer, automatically downloading glucose data to a central location for further analysis. Finally, GlucoChip™ uses RFID technology combined with a tiny embedded bio-sensor system to measure glucose levels in the body in real-time, making it easier than ever to manage your health.

 

These unique devices, designed specifically to advance diabetes management, stand to make a significant impact on the medical industry, revolutionizing diabetes care and treatment for patients, doctors, nurses, health care providers, as well as the families of diabetics.

The Diabetes Problem
In 2010, the World Health Organization estimated 285 million people worldwide had diabetes, or 6.4% of the global adult population. Experts project the number of people suffering from diabetes will double from 2005 to 2030 bringing the worldwide total to 438 million people or 7.8% of the adult population. Clearly an epidemic, Type 2 diabetes has increased in frequency among children. In 2011, the American Diabetes Association estimated about 1 in every 400 children and adolescents under 20 years of age has diabetes.

Diabetes Kills
Diabetes is the second leading cause of death is the United States, as well as the leading cause of kidney failure, non-traumatic lower-limb amputations, and new cases of blindness. Diabetes is also a major cause of heart disease and stroke, according to the Centers for Disease Control and Prevention (CDC). Likely the world’s biggest health challenge in the twenty-first century, diabetes is quickly overtaking the world.

Current Diabetes Management
In order to achieve blood glycemic control, a patient must have the ability to effectively monitor their glucose levels. However, this remains difficult and painful for many people. Currently, checking glucose levels involves pricking the finger to access a drop of blood. This process can be so daunting for patients that it is the primary cause for poor compliance with treatments and ineffective disease management.

Check Glucose Levels Using Exhaled Breath
EasyCheck, a product currently under development by PositiveID Corporation, tests glucose levels in people with diabetes simply by analyzing the breath exhaled by the patient. The small hand-held device actually checks for increased levels of acetone which directly correlate to glucose in the blood. Using advanced microprocessor and laser technology, EasyCheck has built-in self-calibrating capabilities which ensure accuracy.

Once EasyCheck hits the market, it will be the world’s first and only entirely non-invasive glucose tester that provides precise data in a portable device. People with diabetes may finally experience a true breakthrough in glucose management, minimizing difficulty and reducing pain, ultimately encouraging frequent monitoring.

Manage Glucose Data Wirelessly
In addition to developing EasyCheck, PositiveID has also developed iglucose™, an FDA-cleared wireless, seamless device designed to connect to a glucometer and send blood glucose data to a central database where the data is used for better diabetes management. To make life a little easier, iglucose is compatible with data-capable glucometers, providing the patient with flexibility to continue to use their preferred glucometer brand.

PositiveID Corporation recently completed Phase II of their GlucoChip development program, focused on perfecting the glucose sensing system, the critical piece of the implantable GlucoChip device. This new closed-cycle system successfully responds to the body’s glucose levels and provides consistent, measurable results. In other words, the glucose-sensing system works.

Monitor Glucose Levels in Real-Time
Like a gadget from a futuristic movie, GlucoChip will utilize an RFID chip and tiny embedded bio-sensor to measure glucose levels in the body in real-time. Users will be able to read their glucose levels from an external scanner, can use the easy-to-use interface which interacts with the tiny embedded bio-sensor, making it easier than ever to manage your health.

The Rising Cost of Diabetes
Living with diabetes also means living with considerably higher health care costs. Because the prevalence of diabetes keeps climbing, the costs skyrockets. For example, in the United States, health care for diabetics costs roughly 2.3 times higher than for non-diabetic patients. The total costs of diagnosed diabetes in the United States, was $174 billion in 2007, according the American Diabetes Association, which has even gone so far as to create a Diabetes Cost Calculator that takes data from national diabetes costs and gives estimates at the state and congressional district level. Factor in the additional cost of undiagnosed diabetes and the total cost of diabetes in the Unites States in 2007 skyrocketed to $218 billion.

With a growing diabetes pandemic, health care providers will quickly become overloaded and patients will be encouraged both verbally and financially to engage in more self-management, which has shown to be more beneficial anyway. As these new products begin to hit the market, expect growing buzz surrounding these new life-changing products, as they will be very popular in the diabetic community.


About SmallCapVoice.com

SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the penny stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in small cap stocks and micro cap stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.

IMPORTANT DISCLAIMER – PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks

Contact:

Stuart T. Smith CEO
512-267-2430
ssmith@smallcapvoice.com
http://www.smallcapvoice.com

Feeling Sick? Dragonfly Tells You Why on the Fly

This article was originally posted on Smallcapvoice.com.

Once again, PositiveID Corporation aims to transforms the medical industry, this time with a new product called Dragonfly. This innovative company has just received a U.S. Patent for its most rapid molecular diagnostic testing device to date, the Dragonfly (TM) Rapid MDx Cartridge‐based diagnostic system. This amazing new medical technology provides the ability to deliver accurate results in less than half an hour. Imagine knowing the results of your medical tests during the same doctor’s visit, only a few minutes after examination. The future has arrived with Dragonfly. Now, patients can receive a rapid diagnosis in a fraction of the time required for current medical testing procedures.

The Waiting Game of Current Diagnostic Practices

Current diagnostic practices involve lengthy waiting periods often several days long. Without molecular diagnostics, samples must be identified according to their pathology or appearance under a microscope. For example, it can take up to 3 days to get results back from a culture to identify a strep throat infection. Delaying diagnosis usually means delaying treatment. In some cases, this delay of treatment can cause serious complications.

The Importance of Detecting Flu Early

In 2009, the H1N1 flu virus, also called swine flu, caused a worldwide pandemic, the first global pandemic in 40 years. Influenza kills between 250,000 and 550,000 each year. Even though the World Health Organization (WHO) claimed the pandemic ended in August 2010, the virus still circulates like a seasonal flu virus and can affect humans and pigs.

Currently, the most recommended protection against H1N1 flu virus remains a flu vaccine shot, as the preventative serum includes protection against the H1N1 strain, as well as seasonal flu strains. However, since the symptoms of both types of flu are the same, it can be difficult to diagnose which strain a patient has until several days after the disease has taken affect. With the Dragonfly Cartridge, the flu strain can be identified and diagnosed in under 30 minutes. Because the H1N1 virus is expected to continue spreading for years to come, the threat of another serious pandemic looms in our future. Also, the influenza virus evolves rapidly and can cause new strains to quickly replace the older ones, creating a strong need for rapid detection. It can take as long as 6 months for manufacturers to develop and produce the millions of doses essential to treating the seasonal flu surge. The flu endangers all of us. Rapid detection is more important than ever.

Sooner Is Better than Later

As with all communicable diseases, especially air‐borne pathogens, there is a risk of outbreak that can lead to pandemic. Early detection is integral to prevention. Dangerous outbreaks can spread much faster if they go unidentified for very long. Inflected individuals must be quarantined as soon as possible to prevent further infection. The ability to quickly diagnose potentially threatening contagious pathogens drastically changes the likelihood of widespread pandemic.

Dragonfly Diagnoses HPV in Under 30 Minutes

Linked to a range of health problems including cardiovascular disease, genital warts, lung cancer, throat cancer and cervical cancer, more than 120 types of human papillomavirus (HPV) have been identified.

An estimated 490,000 cervical cancer cases, and 270,000 resulting deaths, occur each year and in nearly all cases of cervical cancer, HPV infection was present. 5.2% of all new cancer cases overall are attributed to HPV. This virus has surfaced as one of the most significant infectious causes of cancer, and the most frequent sexually‐transmitted disease in the world.

While pap smears have successfully reduced the incidence of cervical cancer in developed countries, there were still 11,000 cases and 3900 deaths in the United States in 2008 alone. An estimated 80% of American women will be afflicted with at least one strain of genital HPV during their lifetimes.

Current practices typically require 7 to 9 days and up to 3 separate visits to properly test for HPV. Dragonfly will provide actionable diagnostic information from a vaginal/endocervical swab in less than thirty minutes. This unique device has the capability to test for the top 13 types of high‐risk HPV.

Dragonfly Helps in Multiple Applications

Since the Dragonfly Cartridge is so easy to use and affordable, expect to see this device utilized in a wide range of applications, from urgent care or emergency response, HPV testing during regular OB/GYN visits to personalize medicine, and even monitoring for potentially emerging health threats such as the H1N1 virus.

Everyone Will Want Their Own DragonFly

Since the Dragonfly cartridge can be used for so many different applications, this device could become quite popular. According to William J. Caragol, PositiveID Corporation Chairman and CEO, Dragonfly might just “revolutionize the way healthcare is administered by enabling accurate diagnosis within minutes at the point of care, and before the patient leaves the physician’s office.” With this ability to rapidly diagnose certain disease and illness, health professionals can prescribe and implement appropriate treatments right away, therefore reducing unnecessary antibiotics. Dragonfly’s target markets include numerous focuses from regular physician offices and emergency response teams, to military operations and border affairs.

Conclusively, the Dragonfly cartridge could change our world by drastically speeding up health and disease detection, ultimately save more lives.

About SmallCapVoice.com

SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the penny stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in small cap stocks and micro cap stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.

IMPORTANT DISCLAIMER – PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications.

Contact:
Stuart T. Smith CEO
512-267-2430
ssmith@smallcapvoice.com
http://www.smallcapvoice.com

Three New Medical Devices that Change Diabetes Management

This article was originally posted on SmallCapVoice.com.

With three new unique medical devices, Positive ID Corporation (OTCBB: PSID) makes life better for diabetes patients and the people who care for them. All three biological detection products focus on hassle-free ways to measure and manage blood glucose levels.

Manage Glucose Level Data Automatically & Wirelessly
By utilizing wireless technology Positive ID’s product called iglucose makes logging and managing important health data a breeze. iglucose communicates wirelessly and automatically stores data and can easily be setup to share that data with family and health care providers via email, fax or even text message.

Get Real‐time Glucose Levels
GlucoChip uses RFID technology combined with an embedded bio‐sensor system to measure glucose levels in the body in real‐time. The device also includes an easy‐to‐use interface which interacts with the tiny embedded bio‐sensor, making it easier than ever to manage your health.

Easily Check Glucose Levels by Breathing
Currently under development, Easy Check features a noninvasive detection technique that measures the level of acetone in a patient’s breath and correlates that to a blood glucose level. No more painful finger pricking!

Through amazing innovation, Positive ID is changing the way we monitor and manage our health, especially in the field of diabetes and diabetes management. What techniques are you currently using to check blood glucose levels and which of these new solutions appeals to you most and why?


About SmallCapVoice.com

SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the penny stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in small cap stocks and micro cap stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.

IMPORTANT DISCLAIMER – PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications.

Contact:

Stuart T. Smith CEO
512-267-2430
ssmith@smallcapvoice.com
http://www.smallcapvoice.com